Growth Metrics

Lineage Cell Therapeutics (LCTX) Non-Current Deferred Tax Liability (2017 - 2025)

Lineage Cell Therapeutics' Non-Current Deferred Tax Liability history spans 11 years, with the latest figure at $22000.0 for Q4 2025.

  • For Q4 2025, Non-Current Deferred Tax Liability fell 91.94% year-over-year to $22000.0; the TTM value through Dec 2025 reached $22000.0, down 91.94%, while the annual FY2025 figure was $22000.0, 91.94% down from the prior year.
  • Non-Current Deferred Tax Liability reached $22000.0 in Q4 2025 per LCTX's latest filing, down from $273000.0 in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $2.1 million in Q1 2021 to a low of $22000.0 in Q4 2025.
  • Average Non-Current Deferred Tax Liability over 5 years is $914100.0, with a median of $273000.0 recorded in 2023.
  • Peak YoY movement for Non-Current Deferred Tax Liability: soared 132.21% in 2022, then plummeted 91.94% in 2025.
  • A 5-year view of Non-Current Deferred Tax Liability shows it stood at $2.1 million in 2021, then changed by 0.0% to $2.1 million in 2022, then tumbled by 86.85% to $273000.0 in 2023, then changed by 0.0% to $273000.0 in 2024, then tumbled by 91.94% to $22000.0 in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Non-Current Deferred Tax Liability are $22000.0 (Q4 2025), $273000.0 (Q3 2025), and $273000.0 (Q2 2025).